{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.608",
  "meta": {
    "versionId": "5",
    "lastUpdated": "2020-04-29T01:00:18.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.608",
  "version": "20200429",
  "name": "Bone modifying agents",
  "status": "active",
  "date": "2020-04-29T01:00:18-04:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "concept": [
          {
            "code": "1046399",
            "display": "Xgeva"
          },
          {
            "code": "105443",
            "display": "Pamidronate Disodium"
          },
          {
            "code": "11473",
            "display": "pamidronate"
          },
          {
            "code": "1546014",
            "display": "zoledronic acid anhydrous"
          },
          {
            "code": "1546406",
            "display": "pamidronic acid"
          },
          {
            "code": "285143",
            "display": "Zometa"
          },
          {
            "code": "705872",
            "display": "Reclast"
          },
          {
            "code": "77655",
            "display": "zoledronic acid"
          },
          {
            "code": "993449",
            "display": "denosumab"
          },
          {
            "code": "993453",
            "display": "Prolia"
          }
        ]
      }
    ]
  }
}